Interest of Intravitreal Corticotherapy as the First-line Treatment for Post-operative Endophthalmitis

Post-operative Endophthalmitis Clinical Trial

— Endophtalmitis  

Official title:

Interest of Intravitreal Corticotherapy as the First-line Treatment for Post-operative Endophthalmitis.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01768078
• Other study ID #: Creuzot-Garcher PHRC IR 2007
• Status: Completed
• Phase: Phase 3
• Start date: September 2008
• Est. completion date: October 2014

Study information

• Verified date: December 2018
• Source: Centre Hospitalier Universitaire Dijon
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

One useful effect of early intravitreal corticotherapy is to diminish inflammatory complications after endophthalmitis, which may cause, at least in part, serious complications (retinal detachment, macular edema) which are, more than the infection, causes of the complications seen after acute endophthalmitis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 112
• Est. completion date: October 2014
• Est. primary completion date: October 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• All patients male or female with no age limit

• Hospitalized for the diagnosis and treatment of acute endophthalmitis following cataract surgery

• Who had given their consent after being informed about intravitreal corticotherapy

Exclusion Criteria:

• Patients who refused or were unable to give their consent

• Prior intravitreal corticotherapy

Related Conditions & MeSH terms

• Endophthalmitis
• Post-operative Endophthalmitis

Intervention

Procedure:
• Intravitreal injection of Betamethasone + antibiotics

• Intravitreal injection of antibiotics

Locations

Country	Name	City	State
France	CHU de Besançon	Besançon
France	CHU	Dijon
France	CHU de Grenoble	Grenoble
France	CHU de Nancy	Nancy
France	CHU de Saint Etienne	Saint Etienne
France	CHU de Strasbourg	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire Dijon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measure the evolution of visual acuity		up to12 months